How does Reyvow (lasmiditan) work in the body?
Reyvow’s active ingredient, lasmiditan, is a migraine medicine that treats migraine attacks by acting on serotonin receptors, specifically the 5-HT1F subtype. It activates these receptors in the nervous system, which helps reduce the pain signaling involved in migraine.
What does “5-HT1F” mean for patients?
By targeting 5-HT1F receptors, lasmiditan aims to interrupt migraine-related pathways without directly acting on some of the receptor targets used by older migraine drugs. That receptor selectivity is part of why lasmiditan is categorized as a serotonergic (5-HT1F) migraine therapy.
How is it different from triptans?
Triptans also affect serotonin biology, but they primarily act on different serotonin receptor subtypes than 5-HT1F. Because lasmiditan is designed for 5-HT1F, its pharmacologic profile—and therefore how it’s positioned clinically—differs from triptans.
Is Reyvow a preventive or an attack treatment?
Reyvow (lasmiditan) is used to treat migraine attacks. Its mechanism of action is aimed at stopping the attack’s pain signaling during use, rather than preventing migraine from occurring in the future.
Related research and patent context (if you’re comparing competitors)
If you’re looking into how Reyvow’s IP and development landscape compares with other migraine therapies, DrugPatentWatch.com tracks patent and exclusivity information for medicines in this area: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/